Duncan Bridgeman
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
CMC - Appointment of Director
General Capital subsidiary General Finance update
AIA - releases long-term blueprint for the future
April 29th Morning Report
RAK - FY25 Performance and Focus; Director Retirement
PEB - Medicare LCD Effective; Pacific Edge Seeks Recoverage
MEL - New CFO and Executive Changes
PFI - Upgraded FY25 Earnings Guidance
April 28th Morning Report
Mercury appoints new Chief Sustainability Officer